Glioblastoma-targeted CD4+ CAR T cells mediate superior antitumor activity

Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2

Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106 · see citing works

HTSeq—a Python framework to work with high-throughput sequencing data

Anders, S., Pyl, P. T., & Huber, W. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btu638 · Cited by 21,464 · see citing works

TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions.

Kim, D., Pertea, G., Trapnell, C., Pimentel, H., Kelley, R., & Salzberg, S. L. (2013) · Genome Biology · doi:10.1186/gb-2013-14-4-r36 · Cited by 12,668 · see citing works

Molecular and cellular insights into T cell exhaustion

Wherry, E. J., & Kurachi, M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3862 · Cited by 4,652 · see citing works

Wnt signalling in stem cells and cancer

Reya, T., & Clevers, H. (2005) · Nature · doi:10.1038/nature03319 · Cited by 3,666 · see citing works

Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia

Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565 · see citing works

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509 · see citing works

CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients

Turtle, C. J., Hanafi, L.-A., Berger, C., Gooley, T. A., Cherian, S., Hudecek, M., Sommermeyer, D., Melville, K., Pender, B., Budiarto, T. M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85309 · Cited by 2,112 · see citing works

Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation

Anderson, A. C., Joller, N., & Kuchroo, V. K. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.001 · Cited by 2,096 · see citing works

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia

Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063 · see citing works

Viral Immune Evasion Due to Persistence of Activated T Cells Without Effector Function

Zajac, A. J., Blattman, J. N., Murali-Krishna, K., Sourdive, D. J. D., Suresh, M., Altman, J. D., & Ahmed, R. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.12.2205 · Cited by 1,978 · see citing works

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy

Brown, C. E., Alizadeh, D., Starr, R., Weng, L., Wagner, J. R., Naranjo, A., Ostberg, J. R., Blanchard, M. S., Kilpatrick, J., Simpson, J., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610497 · Cited by 1,842 · see citing works

Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection

Eyquem, J., Mansilla-Soto, J., Giavridis, T., van der Stegen, S. J. C., Hamieh, M., Cunanan, K. M., Odak, A., Gönen, M., & Sadelain, M. (2017) · Nature · doi:10.1038/nature21405 · Cited by 1,831 · see citing works

4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors

Long, A. H., Haso, W. M., Shern, J. F., Wanhainen, K. M., Murgai, M., Ingaramo, M., Smith, J. P., Walker, A. J., Kohler, M. E., Venkateshwara, V. R., et al. (2015) · Nature Medicine · doi:10.1038/nm.3838 · Cited by 1,815 · see citing works

Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer

Tran, E., Turcotte, S., Gros, A., Robbins, P. F., Lu, Y., Dudley, M. E., Wunderlich, J. R., Somerville, R. P. T., Hogan, K., Hinrichs, C. S., et al. (2014) · Science · doi:10.1126/science.1251102 · Cited by 1,710 · see citing works

The basic principles of chimeric antigen receptor (CAR) design

Sadelain, M., Brentjens, R., & Rivière, I. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0548 · Cited by 1,423 · see citing works

Exciting New Advances in Neuro-Oncology: The Avenue to a Cure for Malignant Glioma

Van Meir, E. G., Hadjipanayis, C. G., Norden, A. D., Shu, H. K., Wen, P. Y., & Olson, J. J. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20069 · Cited by 1,372 · see citing works

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

Brentjens, R. J., Rivière, I., Park, J. H., Davila, M. L., Wang, X., Stefanski, J., Taylor, C., Yeh, R., Bartido, S. M., Bórquez-Ojeda, O., et al. (2011) · Blood · doi:10.1182/blood-2011-04-348540 · Cited by 1,287 · see citing works

CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection

Matloubian, M., Concepcion, R. J., & Ahmed, R. (1994) · Journal of Virology · doi:10.1128/jvi.68.12.8056-8063.1994 · Cited by 1,162 · see citing works

Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition

Cherkassky, L., Morello, A., Villena‐Vargas, J., Feng, Y., Dimitrov, D. S., Jones, D. R., Sadelain, M., & Adusumilli, P. S. (2016) · Journal of Clinical Investigation · doi:10.1172/jci83092 · Cited by 1,075 · see citing works

Engineered T cells: the promise and challenges of cancer immunotherapy

Fesnak, A. D., June, C. H., & Levine, B. L. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.97 · Cited by 1,074 · see citing works

Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells

Gattinoni, L., Zhong, X.-S., Palmer, D. C., Ji, Y., Hinrichs, C. S., Yu, Z., Wrzesinski, C., Boni, A., Cassard, L., Garvin, L. M., et al. (2009) · Nature Medicine · doi:10.1038/nm.1982 · Cited by 1,031 · see citing works

Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 ⁺ and CD4 ⁺ CD19-specific chimeric antigen receptor–modified T cells

Turtle, C. J., Hanafi, L.-A., Berger, C., Hudecek, M., Pender, B., Robinson, E., Hawkins, R., Chaney, C., Cherian, S., Chen, X., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf8621 · Cited by 1,016 · cited 2× · see citing works

Systemic Immunity Is Required for Effective Cancer Immunotherapy

Spitzer, M. H., Carmi, Y., Reticker-Flynn, N. E., Kwek, S. S., Madhireddy, D., Martins, M. M., Gherardini, P. F., Prestwood, T. R., Chabon, J., Bendall, S. C., et al. (2017) · Cell · doi:10.1016/j.cell.2016.12.022 · Cited by 963 · see citing works

Central memory self/tumor-reactive CD8 + T cells confer superior antitumor immunity compared with effector memory T cells

Klebanoff, C. A., Gattinoni, L., Torabi‐Parizi, P., Kerstann, K. W., Cardones, A. R., Finkelstein, S. E., Palmer, D. C., Antony, P. A., Hwang, S. T., Rosenberg, S. A., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503726102 · Cited by 961 · see citing works

Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells

Gattinoni, L. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24480 · Cited by 947 · see citing works

Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts

Quezada, S. A., Simpson, T. R., Peggs, K. S., Merghoub, T., Vider, J., Fan, X., Blasberg, R., Yagita, H., Muranski, P., Antony, P. A., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20091918 · Cited by 898 · see citing works

Human memory T cells: generation, compartmentalization and homeostasis

Farber, D. L., Yudanin, N. A., & Restifo, N. P. (2014) · Nature Reviews Immunology · doi:10.1038/nri3567 · Cited by 897 · see citing works

Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo

Sommermeyer, D., Hudecek, M., Kosasih, P. L., Gogishvili, T., Maloney, D. G., Turtle, C. J., & Riddell, S. R. (2015) · Leukemia · doi:10.1038/leu.2015.247 · Cited by 864 · see citing works

Tumor-specific Th17-polarized cells eradicate large established melanoma

Muranski, P. J., Boni, A., Antony, P. A., Cassard, L., Irvine, K. R., Kaiser, A., Paulos, C. M., Palmer, D. C., Touloukian, C. E., Ptak, K., et al. (2008) · Blood · doi:10.1182/blood-2007-11-120998 · Cited by 838 · see citing works

Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates

Berger, C., Jensen, M. C., Lansdorp, P. M., Gough, M., Elliott, C., & Riddell, S. R. (2008) · Journal of Clinical Investigation · doi:10.1172/jci32103 · Cited by 822 · see citing works

Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma

Brown, C. E., Badie, B., Barish, M. E., Weng, L., Ostberg, J. R., Chang, W.-C., Naranjo, A., Starr, R., Wagner, J. R., Wright, C. L., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0428 · Cited by 766 · see citing works

High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma

Linnemann, C., van Buuren, M. M., Bies, L., Verdegaal, E. M. E., Schotte, R., Calis, J. J. A., Behjati, S., Velds, A., Hilkmann, H., Atmioui, D. E., et al. (2014) · Nature Medicine · doi:10.1038/nm.3773 · Cited by 671 · see citing works

Paths to stemness: building the ultimate antitumour T cell

Gattinoni, L., Klebanoff, C. A., & Restifo, N. P. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3322 · Cited by 599 · see citing works

Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity

Adusumilli, P. S., Cherkassky, L., Villena‐Vargas, J., Colovos, C., Servais, E. L., Plotkin, J., Jones, D. R., & Sadelain, M. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3010162 · Cited by 572 · see citing works

Molecular and Transcriptional Basis of CD4+ T Cell Dysfunction during Chronic Infection

Crawford, A., Angelosanto, J., Kao, C., Doering, T. A., Odorizzi, P. M., Barnett, B. E., & Wherry, E. J. (2014) · Immunity · doi:10.1016/j.immuni.2014.01.005 · Cited by 495 · see citing works

Primary Antitumor Immune Response Mediated by CD4+ T Cells

Corthay, A., Skovseth, D. K., Lundin, K. U., Røsjø, E., Omholt, H., Hofgaard, P. O., Haraldsen, G., & Bogen, B. (2005) · Immunity · doi:10.1016/j.immuni.2005.02.003 · Cited by 478 · see citing works

Naive tumor-specific CD4+ T cells differentiated in vivo eradicate established melanoma

Xie, Y., Akpınarlı, A., Maris, C. H., Hipkiss, E. L., Lane, M. V., Kwon, E. M., Muranski, P. J., Restifo, N. P., & Antony, P. A. (2010) · The Journal of Experimental Medicine · doi:10.1084/jem.20091921 · Cited by 455 · see citing works

CD4 cells can be more efficient at tumor rejection than CD8 cells

Pérez‐Díez, A., Joncker, N. T., Choi, K., Chan, W. F. N., Anderson, C. C., Lantz, O. J., & Matzinger, P. (2007) · Blood · doi:10.1182/blood-2006-10-051318 · Cited by 436 · see citing works

CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens

de Almeida, L. G. P., Sakabe, N. J., deOliveira, A. R., da Silva, M. C. C., Mundstein, A. S., Cohen, T., Chen, Y., Chua, R., Gurung, S., Gnjatic, S., et al. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn673 · Cited by 436 · see citing works

PD-1 expression on tumor-specific T cells: Friend or foe for immunotherapy?

Simon, S., & Labarrière, N. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1364828 · Cited by 399 · see citing works

Specific Recognition and Killing of Glioblastoma Multiforme by Interleukin 13-Zetakine Redirected Cytolytic T Cells

Kahlon, K. S., Brown, C. E., Cooper, L. J. N., Raubitschek, A. A., Forman, S. J., & Jensen, M. C. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0454 · Cited by 369 · see citing works

ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells

Guedan, S., Chen, X., Madar, A., Carpenito, C., McGettigan, S. E., Frigault, M. J., Lee, J., Posey, A. D., Scholler, J., Scholler, N., et al. (2014) · Blood · doi:10.1182/blood-2013-10-535245 · Cited by 348 · see citing works

Functional interaction between human T-cell protein CD4 and the major histocompatibility complex HLA-DR antigen

Gay, D. L., Maddon, P. J., Sékaly, R., Talle, M. A., Godfrey, M., Long, E. O., Goldstein, G., Chess, L., Axel, R., Kappler, J. W., et al. (1987) · Nature · doi:10.1038/328626a0 · Cited by 345 · see citing works

CD4+ T Cells Contribute to the Remodeling of the Microenvironment Required for Sustained Tumor Regression upon Oncogene Inactivation

Rakhra, K., Bachireddy, P., Zabuawala, T., Zeiser, R., Xu, L., Kopelman, A., Fan, A. C., Yang, Q., Braunstein, L., Crosby, E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.002 · Cited by 339 · see citing works

Insights into Cytokine–Receptor Interactions from Cytokine Engineering

Spangler, J. B., Moraga, I., Mendoza, J. L., & Garcia, K. C. (2015) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120211 · Cited by 304 · see citing works

Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma

Brown, C. E., Aguilar, B., Starr, R., Yang, X., Chang, W.-C., Weng, L., Chang, B., Sarkissian, A., Brito, A., Sanchez, J. F., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.10.002 · Cited by 301 · see citing works

Noncanonical Wnt Signaling Maintains Hematopoietic Stem Cells in the Niche

Sugimura, R., He, X., Venkatraman, A., Arai, F., Box, A., Semerad, C. L., Haug, J. S., Peng, L., Zhong, X.-B., Suda, T., et al. (2012) · Cell · doi:10.1016/j.cell.2012.05.041 · Cited by 292 · see citing works

Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas.

Debinski, W., Gibo, D. M., Hulet, S. W., Connor, J. R., & Gillespie, G. Y. (1999) · PubMed · Cited by 255 · see citing works

Stem-like Tumor-Initiating Cells Isolated from IL13Rα2 Expressing Gliomas Are Targeted and Killed by IL13-Zetakine–Redirected T Cells

Brown, C. E., Starr, R., Aguilar, B., Shami, A. F., Martínez, C., D’Apuzzo, M., Barish, M. E., Forman, S. J., & Jensen, M. C. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1669 · Cited by 227 · see citing works

High-Affinity TCRs Generated by Phage Display Provide CD4+ T Cells with the Ability to Recognize and Kill Tumor Cell Lines

Zhao, Y., Bennett, A., Zheng, Z., Wang, Q. J., Robbins, P. F., Yu, L., Li, Y., Molloy, P. E., Dunn, S. M., Jakobsen, B. K., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.9.5845 · Cited by 221 · see citing works

TCR engagement negatively affects CD8 but not CD4 CAR T cell expansion and leukemic clearance

Yang, Y., Kohler, M. E., Chien, C. D., Sauter, C. T., Jacoby, E., Yan, C., Hu, Y., Wanhainen, K., Qin, H., & Fry, T. J. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aag1209 · Cited by 208 · see citing works

Chimeric Antigen Receptors With Mutated IgG4 Fc Spacer Avoid Fc Receptor Binding and Improve T Cell Persistence and Antitumor Efficacy

Jonnalagadda, M., Mardiros, A., Urak, R. Z., Wang, X., Hoffman, L. J., Bernanke, A., Chang, W.-C., Bretzlaff, W. S., Starr, R., Priceman, S. J., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.208 · Cited by 205 · see citing works

Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment

Scarfò, I., & Maus, M. V. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0230-9 · Cited by 191 · see citing works

Wnt/β-Catenin Signaling in T-Cell Immunity and Cancer Immunotherapy

Gattinoni, L., Ji, Y., & Restifo, N. P. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0356 · Cited by 175 · see citing works

Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy

Thaçi, B., Brown, C. E., Binello, E., Werbaneth, K., Sampath, P., & Sengupta, S. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou045 · Cited by 170 · see citing works

Cytolytic CD4 cells: Direct mediators in infectious disease and malignancy

Brown, D. M. (2010) · Cellular Immunology · doi:10.1016/j.cellimm.2010.02.008 · Cited by 168 · see citing works

Glioma IL13Rα2 Is Associated with Mesenchymal Signature Gene Expression and Poor Patient Prognosis

Brown, C. E., Warden, C., Starr, R., Deng, X., Badie, B., Yuan, Y., Forman, S. J., & Barish, M. E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077769 · Cited by 167 · see citing works

Engraftment of human central memory-derived effector CD8+ T cells in immunodeficient mice

Wang, X., Berger, C., Wong, C. W., Forman, S. J., Riddell, S. R., & Jensen, M. C. (2010) · Blood · doi:10.1182/blood-2010-10-310599 · Cited by 160 · see citing works

Molecular Basis for Shared Cytokine Recognition Revealed in the Structure of an Unusually High Affinity Complex between IL-13 and IL-13Rα2

Lupardus, P. J., Birnbaum, M. E., & García, K. C. (2010) · Structure · doi:10.1016/j.str.2010.01.003 · Cited by 150 · see citing works

Phenotypic and Functional Attributes of Lentivirus-modified CD19-specific Human CD8+ Central Memory T Cells Manufactured at Clinical Scale

Wang, X., Naranjo, A., Brown, C. E., Bautista, C., Wong, C. W., Chang, W.-C., Aguilar, B., Ostberg, J. R., Riddell, S. R., Forman, S. J., et al. (2012) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318270dec7 · Cited by 142 · see citing works

Recognition and Killing of Brain Tumor Stem-Like Initiating Cells by CD8+ Cytolytic T Cells

Brown, C. E., Starr, R., Martínez, C., Aguilar, B., D’Apuzzo, M., Todorov, I., Shih, C.-C., Badie, B., Hudecek, M., Riddell, S. R., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2687 · Cited by 137 · see citing works

Self-antigen–specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response

Rizzuto, G. A., Merghoub, T., Hirschhorn-Cymerman, D., Liu, C., Lesokhin, A. M., Sahawneh, D., Zhong, H., Panageas, K. S., Perales, M., Altan-Bonnet, G. Y., et al. (2009) · The Journal of Experimental Medicine · doi:10.1084/jem.20081382 · Cited by 113 · see citing works

Depletion of naive T cells using clinical grade magnetic CD45RA beads: a new approach for GVHD prophylaxis

Teschner, D., Distler, E., Wehler, D., Frey, M., Marandiuc, D., Langeveld, K., Theobald, M., Thomas, S., & Herr, W. (2013) · Bone Marrow Transplantation · doi:10.1038/bmt.2013.114 · Cited by 90 · see citing works

IL-21 Deficiency Influences CD8 T Cell Quality and Recall Responses following an Acute Viral Infection

Yi, J. S., Ingram, J. T., & Zajac, A. J. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1001032 · Cited by 79 · see citing works

Regulated expression of gp130 and IL-6 receptor alpha chain in T cell maturation and activation.

Betz, U. (1998) · International Immunology · doi:10.1093/intimm/10.8.1175 · Cited by 70 · see citing works

CD45RA depletion in HLA-mismatched allogeneic hematopoietic stem cell transplantation for primary combined immunodeficiency: A preliminary study

Touzot, F., Neven, B., Cortivo, L. D., Gabrion, A., Moshous, D., Cros, G., Chomton, M., Luby, J.-M., Terniaux, B., Magalon, J., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.08.019 · Cited by 69 · see citing works

Smart CARs engineered for cancer immunotherapy

Priceman, S. J., Forman, S. J., & Brown, C. E. (2015) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000232 · Cited by 69 · see citing works

MAGE-6 encodes HLA-DRbeta1*0401-presented epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinoma.

Tatsumi, T., Kierstead, L. S., Ranieri, E., Gesualdo, L., Schena, F. P., Finke, J. H., Bukowski, R. M., Brusić, V., Sidney, J., Sette, A., et al. (2003) · PubMed · Cited by 66 · see citing works

Clonal Abundance of Tumor-Specific CD4 + T Cells Potentiates Efficacy and Alters Susceptibility to Exhaustion

Malandro, N., Budhu, S., Kuhn, N. F., Liu, C., Murphy, J. T., Cortez, C. A., Zhong, H., Yang, X., Rizzuto, G. A., Altan-Bonnet, G. Y., et al. (2016) · Immunity · doi:10.1016/j.immuni.2015.12.018 · Cited by 55 · see citing works

Targeted therapy of solid malignancies via HLA class II antigens: a new biotherapeutic approach?

Altomonte, M., Fonsatti, E., Visintin, A., & Maio, M. (2003) · Oncogene · doi:10.1038/sj.onc.1206960 · Cited by 48 · see citing works

Long-term Persistence of CD4+ but Rapid Disappearance of CD8+ T Cells Expressing an MHC Class I-restricted TCR of Nanomolar Affinity

Engels, B., Chervin, A. S., Sant, A. J., Kranz, D. M., & Schreiber, H. W. (2012) · Molecular Therapy · doi:10.1038/mt.2011.286 · Cited by 48 · see citing works

Similar molecular requirements for antigen receptor-triggered secretion of interferon and granule enzymes by cytolytic T lymphocytes

Fortier, A. H., Nacy, C. A., & Sitkovsky, M. V. (1989) · Cellular Immunology · doi:10.1016/0008-8749(89)90112-3 · Cited by 17 · see citing works

TGFβ biology in cancer progression and immunotherapy

Derynck, R., Turley, S. J., & Akhurst, R. J. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0403-1 · Cited by 944 · see citing works

Revisiting the role of CD4+ T cells in cancer immunotherapy—new insights into old paradigms

Tay, R. E., Richardson, E. K., & Toh, H. C. (2020) · Cancer Gene Therapy · doi:10.1038/s41417-020-0183-x · Cited by 801 · see citing works

IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory Phenotype

Alizadeh, D., Wong, R. A., Yang, X., Wang, D., Pecoraro, J. R., Kuo, C.-F., Aguilar, B., Qi, Y., Ann, D. K., Starr, R., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0466 · Cited by 454 · see citing works

The landscape of the mesenchymal signature in brain tumours

Behnan, J., Finocchiaro, G., & Hanna, G. (2019) · Brain · doi:10.1093/brain/awz044 · Cited by 346 · see citing works

Differentiation and Regulation of TH Cells: A Balancing Act for Cancer Immunotherapy

Basu, A. B., Ramamoorthi, G., Albert, G. K., Gallen, C., Beyer, A., Snyder, C., Koski, G. K., Disis, M. L., Czerniecki, B. J., & Kodumudi, K. N. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.669474 · Cited by 318 · see citing works

A cross-talk between CAR T cell subsets and the tumor microenvironment is essential for sustained cytotoxic activity

Boulch, M., Cazaux, M., Loe-Mie, Y., Thibaut, R., Corre, B., Lemaı̂tre, F., Grandjean, C. L., Garcia, Z., & Bousso, P. (2021) · Science Immunology · doi:10.1126/sciimmunol.abd4344 · Cited by 218 · see citing works

Chlorotoxin-directed CAR T cells for specific and effective targeting of glioblastoma

Wang, D., Starr, R., Chang, W.-C., Aguilar, B., Alizadeh, D., Wright, S. L., Yang, X., Brito, A., Sarkissian, A., Ostberg, J. R., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw2672 · Cited by 215 · see citing works

CAR T‐Cell‐Based gene therapy for cancers: new perspectives, challenges, and clinical developments

Jogalekar, M. P., Rajendran, R. L., Khan, F., Dmello, C., Gangadaran, P., & Ahn, B.-C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.925985 · Cited by 214 · see citing works

CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy

Burger, M. C., Zhang, C., Harter, P. N., Romanski, A., Straßheimer, F., Senft, C., Tonn, T., Steinbach, J. P., & Wels, W. S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02683 · Cited by 211 · see citing works

CAR-T cell performance: How to improve their persistence?

López-Cantillo, G., Urueña, C., Camacho, B. A., & Ramírez-Segura, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.878209 · Cited by 207 · see citing works

In Vivo Generation of CAR T Cells Selectively in Human CD4+ Lymphocytes

Agarwal, S., Hanauer, J. D. S., Frank, A. M., Riechert, V., Thalheimer, F. B., & Buchholz, C. J. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.05.005 · Cited by 190 · see citing works

CRISPR Screening of CAR T Cells and Cancer Stem Cells Reveals Critical Dependencies for Cell-Based Therapies

Wang, D., Prager, B. C., Gimple, R. C., Aguilar, B., Alizadeh, D., Tang, H., Lv, D., Starr, R., Brito, A., Wu, Q., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1243 · Cited by 185 · see citing works

IFNγ Is Critical for CAR T Cell–Mediated Myeloid Activation and Induction of Endogenous Immunity

Alizadeh, D., Wong, R. A., Gholamin, S., Maker, M. S., Aftabizadeh, M., Yang, X., Pecoraro, J. R., Jeppson, J. D., Wang, D., Aguilar, B., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1661 · Cited by 174 · see citing works

The Era of Cytotoxic CD4 T Cells

Cenerenti, M., Saillard, M., Romero, P. J., & Jandus, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.867189 · Cited by 167 · see citing works

Targeting cancers through TCR-peptide/MHC interactions

He, Q., Jiang, X., Zhou, X., & Weng, J. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0812-8 · Cited by 155 · see citing works

Clinical investigation of CAR T cells for solid tumors: Lessons learned and future directions

Bagley, S. J., & O’Rourke, D. M. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107419 · Cited by 143 · see citing works

3D-organoid culture supports differentiation of human CAR+ iPSCs into highly functional CAR T cells

Wang, Z., McWilliams‐Koeppen, H. P., Reza, H., Ostberg, J. R., Chen, W., Wang, X., Huynh, C., Vyas, V., Chang, W.-C., Starr, R., et al. (2022) · Cell stem cell · doi:10.1016/j.stem.2022.02.009 · Cited by 145 · see citing works

Optimizing Manufacturing Protocols of Chimeric Antigen Receptor T Cells for Improved Anticancer Immunotherapy

Stock, S., Schmitt, M. W., & Sellner, L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20246223 · Cited by 143 · see citing works

Tumor-intrinsic sensitivity to the pro-apoptotic effects of IFN-γ is a major determinant of CD4+ CAR T-cell antitumor activity

Boulch, M., Cazaux, M., Cuffel, A., Guérin, M. V., Garcia, Z., Alonso, R., Lemaı̂tre, F., Beer, A., Corre, B., Menger, L., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00570-7 · Cited by 139 · see citing works

Role of T cells in cancer immunotherapy: Opportunities and challenges

Ahmed, H., Mahmud, A. R., Siddiquee, M. F. R., Shahriar, A., Biswas, P., Shimul, M. E. K., Ahmed, S. Z., Ema, T. I., Rahman, N., Khan, M. A., et al. (2022) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2022.12.002 · Cited by 140 · see citing works

CTLA-4 blockade induces a microglia-Th1 cell partnership that stimulates microglia phagocytosis and anti-tumor function in glioblastoma

Chen, D., Varanasi, S. K., Hara, T., Traina, K. A., Sun, M. H., McDonald, B., Farsakoglu, Y., Clanton, J., Xu, S., Garcia-Rivera, L., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.07.015 · Cited by 113 · see citing works

An IL-4/21 Inverted Cytokine Receptor Improving CAR-T Cell Potency in Immunosuppressive Solid-Tumor Microenvironment

Wang, Y., Jiang, H., Luo, H., Sun, Y., Shi, B., Sun, R., & Li, Z. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01691 · Cited by 111 · see citing works

Glioblastoma Immune Landscape and the Potential of New Immunotherapies

Daubon, T., Hémadou, A., Garmendia, I. R., & Saleh, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.585616 · Cited by 107 · see citing works

EZH1 repression generates mature iPSC-derived CAR T cells with enhanced antitumor activity

Jing, R., Scarfò, I., Najia, M. A. T., da Rocha, E. L., Han, A., Sanborn, M., Bingham, T., Kubaczka, C., Jha, D. K., Falchetti, M., et al. (2022) · Cell stem cell · doi:10.1016/j.stem.2022.06.014 · Cited by 96 · see citing works

Understanding CAR T cell-tumor interactions: Paving the way for successful clinical outcomes

Korell, F., Berger, T. R., & Maus, M. V. (2022) · Med · doi:10.1016/j.medj.2022.05.001 · Cited by 96 · see citing works

Strategies to enhance CAR-T persistence

Liu, Y., An, L., Huang, R., Xiong, J., Yang, H., Wang, X., & Zhang, X. (2022) · Biomarker Research · doi:10.1186/s40364-022-00434-9 · Cited by 97 · see citing works

GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma

Park, J. A., & Cheung, N.-K. V. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01012-y · Cited by 88 · see citing works

Hypoxia Selectively Impairs CAR-T Cells In Vitro

Berahovich, R., Liu, X., Zhou, H., Tsadik, E., Xu, S., Golubovskaya, V., & Wu, L. (2019) · Cancers · doi:10.3390/cancers11050602 · Cited by 94 · see citing works

Determinants of response and resistance to CAR T cell therapy

Lesch, S., Benmebarek, M.-R., Cadilha, B. L., Stoiber, S., Subklewe, M. S., Endres, S., & Kobold, S. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.11.004 · Cited by 93 · see citing works

Engineering better chimeric antigen receptor T cells

Zhang, H., Zhao, P., & Huang, H. (2020) · Experimental Hematology & Oncology · doi:10.1186/s40164-020-00190-2 · Cited by 93 · see citing works

Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy

Bulliard, Y., Andersson, B. S., Baysal, M. A., Damiano, J. S., & Tsimberidou, A. M. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01504-7 · Cited by 95 · see citing works

Universal redirection of CAR T cells against solid tumours via membrane-inserted ligands for the CAR

Zhang, A. Q., Hostetler, A., Chen, L. E., Mukkamala, V., Abraham, W. D., Padilla, L. T., Wolff, A. N., Maiorino, L., Backlund, C. M., Aung, A., et al. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01048-8 · Cited by 91 · see citing works

Different T-cell subsets in glioblastoma multiforme and targeted immunotherapy

Wang, H., Zhou, H., Xu, J., Lu, Y., Ji, X., Yao, Y., Hou, C., Zhang, J., Zhang, X., Yao, S., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.09.028 · Cited by 87 · see citing works

Persistent STAT5 activation reprograms the epigenetic landscape in CD4 + T cells to drive polyfunctionality and antitumor immunity

Ding, Z., Shi, H., Aboelella, N. S., Fesenkova, K., Park, E.-J., Liu, Z., Pei, L., Li, J., McIndoe, R., Xu, H., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.aba5962 · Cited by 80 · see citing works

CD4+ Cytotoxic T cells – Phenotype, Function and Transcriptional Networks Controlling Their Differentiation Pathways

Preglej, T., & Ellmeier, W. (2022) · Immunology Letters · doi:10.1016/j.imlet.2022.05.001 · Cited by 82 · see citing works

Next Generation CAR T Cells for the Immunotherapy of High-Grade Glioma

Petersen, C. T., & Krenciute, G. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00069 · Cited by 79 · see citing works

CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment

Seyfrid, M., Maich, W. T., Shaikh, M. V., Tatari, N., Upreti, D., Piyasena, D., Subapanditha, M., Savage, N. J., McKenna, D., Mikolajewicz, N., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003289 · Cited by 77 · see citing works

Genetically Engineered T-Cells for Malignant Glioma: Overcoming the Barriers to Effective Immunotherapy

Chuntova, P., Downey, K., Hegde, B., Almeida, N. D., & Okada, H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03062 · Cited by 70 · see citing works

Tumor Interferon Signaling Is Regulated by a lncRNA INCR1 Transcribed from the PD-L1 Locus

Mineo, M., Lyons, S. M., Zdioruk, M. I., von Spreckelsen, N., Ferrer-Luna, R., Ito, H., Alayo, Q. A., Kharel, P., Giantini-Larsen, A., Fan, W. Y., et al. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.05.015 · Cited by 70 · see citing works

Targeting senescent cells with NKG2D-CAR T cells

Deng, Y., Kumar, A., Xie, K., Schaaf, K., Scifo, E., Morsy, S., Li, T., Ehninger, A., Bano, D., & Ehninger, D. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-01976-7 · Cited by 70 · see citing works

Preclinical Evaluation of CAR T Cell Function: In Vitro and In Vivo Models

Si, X., Xiao, L., Brown, C. E., & Wang, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063154 · Cited by 69 · see citing works

Regulation and impact of tumor-specific CD4+ T cells in cancer and immunotherapy

Guo, M., Liu, M. Y. R., & Brooks, D. G. (2024) · Trends in Immunology · doi:10.1016/j.it.2024.02.005 · Cited by 66 · see citing works

Investigation of the Impact from IL-2, IL-7, and IL-15 on the Growth and Signaling of Activated CD4+ T Cells

Coppola, C. D., Hopkins, B., Huhn, S. C., Du, Z., Huang, Z. J., & Kelly, W. J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21217814 · Cited by 65 · see citing works

CD4+ T Cells: Multitasking Cells in the Duty of Cancer Immunotherapy

Richardson, J. R., Schöllhorn, A., Gouttefangeas, C., & Schuhmacher, J. (2021) · Cancers · doi:10.3390/cancers13040596 · Cited by 64 · see citing works

Role and Potential of Different T Helper Cell Subsets in Adoptive Cell Therapy

Andreu-Sanz, D., & Kobold, S. (2023) · Cancers · doi:10.3390/cancers15061650 · Cited by 61 · see citing works

CD4 CAR-T cells targeting CD19 play a key role in exacerbating cytokine release syndrome, while maintaining long-term responses

Bove, C., Arcangeli, S., Falcone, L., Camisa, B., Khoury, R. E., Greco, B. M., Lucia, A. D., Bergamini, A., Bondanza, A., Ciceri, F., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005878 · Cited by 61 · see citing works

PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies

Jie, Y., Liu, G., Feng, L., Li, Y., Mingyan, E., Wu, L., Li, Y., Rong, G., Li, Y., Wei, H., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.665970 · Cited by 60 · see citing works

Vaccination against RhoC induces long-lasting immune responses in patients with prostate cancer: results from a phase I/II clinical trial

Schuhmacher, J., Heidu, S., Balchen, T., Richardson, J. R., Schmeltz, C., Sonne, J., Schweiker, J., Rammensee, H., Straten, P. T., Røder, M. A., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001157 · Cited by 61 · see citing works

Harnessing Antitumor CD4+ T Cells for Cancer Immunotherapy

Khelil, M. B., Godet, Y., Abdeljaoued, S., Borg, C., Adotévi, O., & Loyon, R. (2022) · Cancers · doi:10.3390/cancers14010260 · Cited by 58 · see citing works

Genetic Modification Strategies to Enhance CAR T Cell Persistence for Patients With Solid Tumors

DeRenzo, C. C., & Gottschalk, S. M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00218 · Cited by 58 · see citing works

CAR T cells and checkpoint inhibition for the treatment of glioblastoma

Shen, S. H., Woroniecka, K. I., Barbour, A. B., Fecci, P. E., Sanchez-Perez, L. A., & Sampson, J. H. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1727436 · Cited by 59 · see citing works

The outstanding antitumor capacity of CD4+ T helper lymphocytes

Li, T., Wu, B., Yang, T., Zhang, L., & Jin, K. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188439 · Cited by 57 · see citing works

Intratumoral pan-ErbB targeted CAR-T for head and neck squamous cell carcinoma: interim analysis of the T4 immunotherapy study

Papa, S., Adami, A. A., Metoudi, M., Beatson, R., George, M., Achkova, D. Y., Williams, E., Arif, S., Reid, F., Elstad, M., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007162 · Cited by 57 · see citing works

Harnessing neoantigen specific CD4 T cells for cancer immunotherapy

Brightman, S. E., Naradikian, M. S., Miller, A. M., & Schoenberger, S. P. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.5ri0220-603rr · Cited by 56 · see citing works

Knowns and Unknowns about CAR-T Cell Dysfunction

Titov, A., Kaminskiy, Y., Ganeeva, I., Zmievskaya, E., Valiullina, A., Rakhmatullina, A., Petukhov, A., Рифкатовна, М. Р., Rizvanov, A. A., & Bulatov, E. (2022) · Cancers · doi:10.3390/cancers14041078 · Cited by 56 · see citing works

Enhancing anti-EGFRvIII CAR T cell therapy against glioblastoma with a paracrine SIRPγ-derived CD47 blocker

Martins, T. A., Kaymak, D., Tatari, N., Gerster, F., Hogan, S., Ritz, M.-F., Sabatino, V., Wieboldt, R., Bartoszek, E. M., McDaid, M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54129-w · Cited by 54 · see citing works

Evidence of long‐lasting anti‐CD19 activity of engrafted CD19 chimeric antigen receptor–modified T cells in a phase I study targeting pediatrics with acute lymphoblastic leukemia

Ma, F., Ho, J., Du, H., Fan, X., Wu, X., Wang, Q., Wang, L., Liu, Y., Ba, M., Wang, Y., et al. (2019) · Hematological Oncology · doi:10.1002/hon.2672 · Cited by 51 · see citing works

HIV-Resistant and HIV-Specific CAR-Modified CD4+ T Cells Mitigate HIV Disease Progression and Confer CD4+ T Cell Help In Vivo

Maldini, C. R., Gayout, K., Leibman, R. S., Dopkin, D. L., Mills, J. P., Shan, X., Glover, J. A., & Riley, J. L. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.05.012 · Cited by 48 · see citing works

Impact of the selective A2AR and A2BR dual antagonist AB928/etrumadenant on CAR T cell function

Seifert, M., Benmebarek, M.-R., Briukhovetska, D., Märkl, F., Dörr, J., Cadilha, B. L., Jobst, J., Stock, S., Andreu-Sanz, D., Lorenzini, T., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-02013-z · Cited by 48 · see citing works

The role of CD4+ T cells in tumor and chronic viral immune responses

Xie, L., Fang, J., Yu, J., Zhang, W., He, Z., Ye, L., & Wang, H. (2023) · MedComm · doi:10.1002/mco2.390 · Cited by 50 · see citing works

MEK inhibition prevents CAR-T cell exhaustion and differentiation via downregulation of c-Fos and JunB

Wang, X., Xiao, T., Chen, P., Jiang, P., Li, W., Chang, H., Wei, C., Lai, X., Zhang, H., Pan, Y., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01986-y · Cited by 48 · see citing works

Challenges and limitations of chimeric antigen receptor T-cell therapies in solid tumors: why are approvals restricted to hematologic malignancies?

Vo, M.-C., Tran, V.-D.-H., Nguyen, V., Ruzimurodov, N., Trung, D. T., Kim, S. K., Jung, S., & Lee, J. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01744-9 · Cited by 55 · see citing works

Oligonucleotide Therapeutics as a New Class of Drugs for Malignant Brain Tumors: Targeting mRNAs, Regulatory RNAs, Mutations, Combinations, and Beyond

Krichevsky, A. M., & Uhlmann, E. J. (2019) · Neurotherapeutics · doi:10.1007/s13311-018-00702-3 · Cited by 47 · see citing works

Distinct Stromal and Immune Features Collectively Contribute to Long-Term Survival in Pancreatic Cancer

Sadozai, H., Acharjee, A., Eppenberger‐Castori, S., Gloor, B., Gruber, T., Schenk, M., & Karamitopoulou, E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.643529 · Cited by 47 · see citing works

Switch receptor T3/28 improves long-term persistence and antitumor efficacy of CAR-T cells

Zhao, S., Wang, C., Lu, P., Lou, Y., Liu, H., Wang, T., Yang, S., Bao, Z., Han, L. G., Liang, X., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003176 · Cited by 45 · see citing works

T Cell Reprogramming Against Cancer

Katz, S. G., & Rabinovich, P. M. (2019) · Methods in molecular biology · doi:10.1007/978-1-0716-0203-4_1 · Cited by 44 · see citing works

Activated NK cells reprogram MDSCs via NKG2D-NKG2DL and IFN-γ to modulate antitumor T-cell response after cryo-thermal therapy

Peng, P., Lou, Y., Wang, S., Wang, J., Zhang, Z., Du, P., Zheng, J., Liu, P., & Xu, L. X. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005769 · Cited by 43 · see citing works

Optimization of manufacturing conditions for chimeric antigen receptor T cells to favor cells with a central memory phenotype

Gargett, T., Truong, N. T., Ebert, L. M., Yu, W., & Brown, M. P. (2019) · Cytotherapy · doi:10.1016/j.jcyt.2019.03.003 · Cited by 39 · see citing works

Clinical chimeric antigen receptor‐T cell therapy: a new and promising treatment modality for glioblastoma

Brown, M. P., Ebert, L. M., & Gargett, T. (2019) · Clinical & Translational Immunology · doi:10.1002/cti2.1050 · Cited by 40 · see citing works

Novel high‐affinity EGFRvIII‐specific chimeric antigen receptor T cells effectively eliminate human glioblastoma

Abbott, R. C., Verdon, D. J., Gracey, F. M., Hughes‐Parry, H. E., Iliopoulos, M., Watson, K. A., Mulazzani, M., Luong, K., D’Arcy, C. E., Sullivan, L. C., et al. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1283 · Cited by 38 · see citing works

Epigenetic Reprogramming of CD4+ Helper T Cells as a Strategy to Improve Anticancer Immunotherapy

Renaude, E., Kroemer, M., Borg, C., Peixoto, P., Hervouet, É., Loyon, R., & Adotévi, O. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.669992 · Cited by 40 · see citing works

Current and Future Roles of Chimeric Antigen Receptor T-Cell Therapy in Neurology

Ismail, F. S., Gallus, M., Meuth, S. G., Okada, H., Hartung, H.-P., & Melzer, N. (2024) · JAMA Neurology · doi:10.1001/jamaneurol.2024.3818 · Cited by 41 · see citing works

Histone deacetylases 1 and 2 restrain CD4+ cytotoxic T lymphocyte differentiation

Preglej, T., Hamminger, P., Luu, M., Bulat, T., Andersen, L., Göschl, L., Stolz, V., Rica, R., Sandner, L., Waltenberger, D., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.133393 · Cited by 36 · see citing works

Predicting T‐cell quality during manufacturing through an artificial intelligence‐based integrative multiomics analytical platform

Odeh‐Couvertier, V. Y., Dwarshuis, N. J., Colonna, M. B., Levine, B. L., Edison, A. S., Kotanchek, T., Roy, K., & Torres‐García, W. (2021) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10282 · Cited by 33 · see citing works

Harnessing type I interferon-mediated immunity to target malignant brain tumors

Lim, J., Kang, I., La, J., Ku, K. B., Kang, B. H., Kim, Y., Park, W. H., & Lee, H. K. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1203929 · Cited by 35 · see citing works

Potential of Glioblastoma-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy

Salinas, R. D., Durgin, J. S., & O’Rourke, D. M. (2020) · CNS Drugs · doi:10.1007/s40263-019-00687-3 · Cited by 34 · see citing works

Anti-CAIX BBζ CAR4/8 T cells exhibit superior efficacy in a ccRCC mouse model

Wang, Y., Buck, A., Grimaud, M., Culhane, A. C., Kodangattil, S. R., Razimbaud, C., Bonal, D. M., Nguyen, Q., Zhu, Z., Wei, K. S., et al. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.12.019 · Cited by 33 · see citing works

Single-cell transcriptomics identifies multiple pathways underlying antitumor function of TCR- and CD8αβ-engineered human CD4 + T cells

Rath, J. A., Bajwa, G., Carrères, B. M., Hoyer, E. A., Gruber, I., Martinez-Paniagua, M. A., Yu, Y.-R., Nouraee, N., Sadeghi, F., Wu, M., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz7809 · Cited by 30 · see citing works

Pre-clinical validation of a pan-cancer CAR-T cell immunotherapy targeting nfP2X7

Bandara, V., Foeng, J., Gundsambuu, B., Norton, T. S., Nápoli, S., McPeake, D. J., Tyllis, T. S., Rad, E. R., Abbott, C. A., Mills, S. J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41338-y · Cited by 33 · see citing works

Contextual Reprogramming of CAR-T Cells for Treatment of HER2+ Cancers

Yang, Z., Li, L., Turkoz, A., Chen, P., Harari-Steinfeld, R., Bobbin, M. L., Stefanson, O., Choi, H., Pietrobon, V., Alphson, B., et al. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-021-03132-6 · Cited by 32 · see citing works

Development of HIV-Resistant CAR T Cells by CRISPR/Cas-Mediated CAR Integration into the CCR5 Locus

Rothemejer, F. H., Lauritsen, N. P., Juhl, A. K., Schleimann, M. H., König, S., Søgaard, O. S., Bak, R. O., & Tolstrup, M. (2023) · Viruses · doi:10.3390/v15010202 · Cited by 31 · see citing works

Genetic Abnormalities, Clonal Evolution, and Cancer Stem Cells of Brain Tumors

Testa, U., Castelli, G., & Pelosi, E. (2018) · Medical Sciences · doi:10.3390/medsci6040085 · Cited by 30 · see citing works

Generating allogeneic CAR-NKT cells for off-the-shelf cancer immunotherapy with genetically engineered HSP cells and feeder-free differentiation culture

Li, Y.-R., Zhou, K., Lee, D., Zhu, Y., Halladay, T., Yu, J., Zhou, Y., Lyu, Z., Fang, Y., Chen, Y., et al. (2025) · Nature Protocols · doi:10.1038/s41596-024-01077-w · Cited by 30 · see citing works

Targeting interleukin-13 receptor α2 (IL-13Rα2) for glioblastoma therapy with surface functionalized nanocarriers

Liang, R., Wu, C., Liu, S., & Zhao, W. (2022) · Drug Delivery · doi:10.1080/10717544.2022.2075986 · Cited by 28 · see citing works

EGFR as a potent CAR T target in triple negative breast cancer brain metastases

Subham, S., Jeppson, J. D., Worcester, C. R., Schatmeyer, B. A., Zhao, J., Madan, R., Lakis, N. S., Kimler, B. F., McGuirk, J. P., Chen, R. C., et al. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06783-1 · Cited by 28 · see citing works

Chimeric antigen receptor modified T cell (CAR-T) co-expressed with ICOSL-41BB promote CAR-T proliferation and tumor rejection

Hu, W., Huang, X., Huang, X., Chen, W., Hao, L.-D., & Chen, Z. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109333 · Cited by 28 · see citing works

Paving New Roads for CARs

Wittsten, A. H., & Roybal, K. T. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.09.005 · Cited by 27 · see citing works

c-Met specific CAR-T cells as a targeted therapy for non-small cell lung cancer cell A549

Min, J., Long, C., Zhang, L., Duan, J., Fan, H., Chu, F., & Li, Z. (2022) · Bioengineered · doi:10.1080/21655979.2022.2058149 · Cited by 28 · see citing works

Cell Granularity Reflects Immune Cell Function and Enables Selection of Lymphocytes with Superior Attributes for Immunotherapy

Wu, T., Tan, J. H. L., Sin, W., Luah, Y. H., Tan, S. Y., Goh, M., Birnbaum, M. E., Chen, Q., & Cheow, L. F. (2023) · Advanced Science · doi:10.1002/advs.202302175 · Cited by 26 · see citing works

Chimeric Antigen Receptor T Cells in Glioblastoma—Current Concepts and Promising Future

Kringel, R., Lamszus, K., & Mohme, M. (2023) · Cells · doi:10.3390/cells12131770 · Cited by 26 · see citing works

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

Wang, D., Starr, R., Alizadeh, D., Yang, X., Forman, S. J., & Brown, C. E. (2019) · Journal of Visualized Experiments · doi:10.3791/59275 · Cited by 26 · see citing works

Engineering for Success: Approaches to Improve Chimeric Antigen Receptor T Cell Therapy for Solid Tumors

Mata, M., & Gottschalk, S. M. (2019) · Drugs · doi:10.1007/s40265-019-01071-7 · Cited by 25 · see citing works

Enhanced Chimeric Antigen Receptor T Cell Therapy through Co-Application of Synergistic Combination Partners

Stock, S., Kluever, A.-K., Endres, S., & Kobold, S. (2022) · Biomedicines · doi:10.3390/biomedicines10020307 · Cited by 25 · see citing works

Charting the Course: Sequencing Immunotherapy for Multiple Myeloma

Mohan, M., Oekelen, O. V., Akhtar, O. S., Cohen, A. D., & Parekh, S. S. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_432204 · Cited by 27 · see citing works

Engineering resilient CAR T cells for immunosuppressive environment

Khalifeh, M., & Salman, H. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.01.035 · Cited by 24 · see citing works

Vaccine-based immunotherapy and related preclinical models for glioma

Yao, L., Hatami, M., Ma, W., & Skutella, T. (2024) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2024.06.009 · Cited by 24 · see citing works

Keeping Myeloma in Check: The Past, Present and Future of Immunotherapy in Multiple Myeloma

Ackley, J. C., Ochoa, M. A., Ghoshal, D., Roy, K., Lonial, S., & Boise, L. (2021) · Cancers · doi:10.3390/cancers13194787 · Cited by 24 · see citing works

Impact of Immunotherapy on CD4 T Cell Phenotypes and Function in Cancer

Saillard, M., Cenerenti, M., Romero, P., & Jandus, C. (2021) · Vaccines · doi:10.3390/vaccines9050454 · Cited by 23 · see citing works

Pharmacodynamic changes in tumor and immune cells drive iberdomide’s clinical mechanisms of activity in relapsed and refractory multiple myeloma

Amatangelo, M. D., Flynt, E., Stong, N., Ray, P. R., Oekelen, O. V., Wang, M., Ortiz, M., Maciag, P., Peluso, T., Parekh, S. S., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101571 · Cited by 23 · see citing works

Multi-Omics Analysis Reveals Novel Subtypes and Driver Genes in Glioblastoma

Yang, Y., Pan, Q., Xiang, W., Yanhui, L., Li, Y., & Mao, Q. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.565341 · Cited by 23 · see citing works

198. CD4+ IL13Rα2-Specific CAR T Cells Exhibit Potent Effector Function Against Glioblastoma

Wang, D., Starr, R., Aguilar, B., Brito, A., Chang, B., Sarkissian, A., Badie, B., Barish, M. E., Forman, S. J., & Brown, C. E. (2016) · Molecular Therapy · doi:10.1016/s1525-0016(16)33007-6

Abstract 3024: CD4+ outperform CD8+ central memory-derived CAR T cells, mediating persistent antitumor responses and long-term eradication of glioblastoma

Wang, D., Starr, R., Aguilar, B., Brito, A., Chang, B., Sarkissian, A., Badie, B., Barish, M. E., Forman, S. J., & Brown, C. E. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-3024

The development and potent antitumor efficacy of CD44/CD133 dual-targeting IL7Rα-armored CAR-T cells against glioblastoma

Zhai, Y., Li, G., Pan, C., Yu, M., Hu, H., Wang, D., Shi, Z., Jiang, T., & Zhang, W. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217541 · Cited by 33 · see citing works

P06.01 Functional analysis of IL13Rα2-specific chimeric antigen receptor T cells in immunocompetent mouse of glioblastoma

Pituch, K. C., Miska, J. M., Krenciute, G., Li, G., Panek, W. K., Gottschalk, S. M., & Balyasnikova, I. V. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox036.175

CAR T-cell therapy for glioblastoma: ready for the next round of clinical testing?

Prinzing, B. L., Gottschalk, S. M., & Krenciute, G. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1451749 · Cited by 22 · see citing works